$71.89
+0.14
(+0.2%)▲
0.33%
Downside
Day's Volatility :1.97%
Upside
1.64%
39.64%
Downside
52 Weeks Volatility :41.49%
Upside
3.06%
Period | Globus Medical, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 41.94% | 6.5% | 0.0% |
6 Months | 33.49% | 7.1% | 0.0% |
1 Year | 15.26% | 9.8% | 0.0% |
3 Years | -13.46% | 14.2% | -20.2% |
Market Capitalization | 9.8B |
Book Value | $29.04 |
Earnings Per Share (EPS) | 0.54 |
PE Ratio | 134.56 |
PEG Ratio | 1.75 |
Wall Street Target Price | 68.38 |
Profit Margin | 3.51% |
Operating Margin TTM | 13.71% |
Return On Assets TTM | 5.27% |
Return On Equity TTM | 2.28% |
Revenue TTM | 1.9B |
Revenue Per Share TTM | 15.58 |
Quarterly Revenue Growth YOY | 119.30000000000001% |
Gross Profit TTM | 759.1M |
EBITDA | 480.8M |
Diluted Eps TTM | 0.54 |
Quarterly Earnings Growth YOY | -0.79 |
EPS Estimate Current Year | 2.82 |
EPS Estimate Next Year | 3.31 |
EPS Estimate Current Quarter | 0.57 |
EPS Estimate Next Quarter | 0.66 |
What analysts predicted
Downside of 4.88%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 713.0M | ↑ 12.11% |
Net Income | 156.5M | ↑ 45.76% |
Net Profit Margin | 21.95% | ↑ 5.07% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 785.4M | ↑ 10.15% |
Net Income | 155.2M | ↓ 0.81% |
Net Profit Margin | 19.76% | ↓ 2.19% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 789.0M | ↑ 0.47% |
Net Income | 102.3M | ↓ 34.1% |
Net Profit Margin | 12.96% | ↓ 6.8% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 958.1M | ↑ 21.43% |
Net Income | 149.2M | ↑ 45.86% |
Net Profit Margin | 15.57% | ↑ 2.61% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 6.76% |
Net Income | 190.2M | ↑ 27.47% |
Net Profit Margin | 18.59% | ↑ 3.02% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↑ 53.34% |
Net Income | 122.9M | ↓ 35.39% |
Net Profit Margin | 7.83% | ↓ 10.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 274.5M | ↑ 8.01% |
Net Income | 50.1M | ↑ 5.55% |
Net Profit Margin | 18.24% | ↓ 0.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 276.7M | ↑ 0.8% |
Net Income | 49.1M | ↓ 1.87% |
Net Profit Margin | 17.76% | ↓ 0.48% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 291.6M | ↑ 5.39% |
Net Income | 57.7M | ↑ 17.47% |
Net Profit Margin | 19.79% | ↑ 2.03% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 383.6M | ↑ 31.56% |
Net Income | 998.0K | ↓ 98.27% |
Net Profit Margin | 0.26% | ↓ 19.53% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 616.5M | ↑ 60.71% |
Net Income | 15.0M | ↑ 1406.41% |
Net Profit Margin | 2.44% | ↑ 2.18% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 606.7M | ↓ 1.6% |
Net Income | -7.1M | ↓ 147.34% |
Net Profit Margin | -1.17% | ↓ 3.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 20.6% |
Total Liabilities | 115.2M | ↑ 4.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 17.79% |
Total Liabilities | 129.6M | ↑ 12.57% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 9.62% |
Total Liabilities | 173.2M | ↑ 33.61% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 16.54% |
Total Liabilities | 215.9M | ↑ 24.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 6.07% |
Total Liabilities | 229.8M | ↑ 6.43% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 5.1B | ↑ 144.98% |
Total Liabilities | 1.1B | ↑ 373.61% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↑ 5.04% |
Total Liabilities | 229.8M | ↑ 8.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↑ 3.54% |
Total Liabilities | 234.8M | ↑ 2.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 2.92% |
Total Liabilities | 227.4M | ↓ 3.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.4B | ↑ 142.08% |
Total Liabilities | 1.2B | ↑ 413.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.1B | ↓ 5.04% |
Total Liabilities | 1.1B | ↓ 6.89% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 4.9B | ↓ 2.8% |
Total Liabilities | 1.0B | ↓ 6.15% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 181.6M | ↑ 13.86% |
Investing Cash Flow | -193.0M | ↑ 73.47% |
Financing Cash Flow | 32.6M | ↑ 1903.08% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 172.0M | ↓ 5.32% |
Investing Cash Flow | -140.3M | ↓ 27.33% |
Financing Cash Flow | 24.4M | ↓ 24.96% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 198.8M | ↑ 15.59% |
Investing Cash Flow | -117.3M | ↓ 16.37% |
Financing Cash Flow | -38.7M | ↓ 258.2% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 276.3M | ↑ 38.98% |
Investing Cash Flow | -375.9M | ↑ 220.43% |
Financing Cash Flow | 54.1M | ↓ 240.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 178.5M | ↓ 35.4% |
Investing Cash Flow | -110.4M | ↓ 70.64% |
Financing Cash Flow | -110.0M | ↓ 303.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 64.0M | ↑ 94.33% |
Investing Cash Flow | -60.5M | ↓ 4.16% |
Financing Cash Flow | 13.6M | ↑ 3.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 53.3M | ↓ 16.67% |
Investing Cash Flow | 11.0M | ↓ 118.17% |
Financing Cash Flow | 2.9M | ↓ 78.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.0M | ↓ 34.3% |
Investing Cash Flow | 52.2M | ↑ 375.09% |
Financing Cash Flow | 1.1M | ↓ 63.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 50.5M | ↑ 44.12% |
Investing Cash Flow | -80.9M | ↓ 254.84% |
Financing Cash Flow | 1.4M | ↑ 31.46% |
Sell
Neutral
Buy
Globus Medical, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Globus Medical, Inc. | 5.42% | 33.49% | 15.26% | -13.46% | 61.82% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Globus Medical, Inc. | 134.56 | 134.56 | 1.75 | 2.82 | 0.02 | 0.05 | NA | 29.04 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Globus Medical, Inc. | Buy | $9.8B | 61.82% | 134.56 | 3.51% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Globus Medical, Inc.
Revenue is down for the last 2 quarters, 616.53M → 606.66M (in $), with an average decrease of 1.6% per quarter
Netprofit is down for the last 2 quarters, 15.03M → -7.11M (in $), with an average decrease of 147.3% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 26.4%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 82.4%
Vanguard Group Inc
BlackRock Inc
HHG PLC
State Street Corporation
Wellington Management Company LLP
Bank of New York Mellon Corp
globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
Organization | Globus Medical, Inc. |
Employees | 5000 |
CEO | Mr. David C. Paul |
Industry | Health Technology |